Crysvita® (burosumab-twza) – Expanded indication
September 30, 2019 - Ultragenyx and Kyowa Kirin announced the FDA approval of Crysvita (burosumab-twza), for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older.
Download PDF
